Pfizer Investigational Site
New Haven, Connecticut, 06511, United States
NCT Number: NCT01821079
The purpose of this study in healthy volunteers is to assess the relative bioavailability of PF-05175157 as powder-in-capsule and a tablet formulation and the effect of food on the pharmacokinetics of the tablet formulation.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
New Haven, Connecticut, 06511, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Single 200 mg dose of PF-05175157 administered as powder in capsule (2x100 mg)
Time frame: 0 to 72 H after dose
Time frame: 0 to 72 H after dose
Time frame: 0 to 72 H after dose
Time frame: 0 to 72 H after dose
Time frame: 0 to 72 H after dose
Pfizer
Industry
A Phase 1, Single-Dose, Open-Label, Crossover Study To Assess The Relative Bioavailability Of Powder-In-Capsule And A Tablet Formulation Of Pf-05175157 And The Effect Of Food On The Pharmacokinetics Of The Tablet Formulation In Healthy Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06869018
Diabetes Mellitus, Diabetes Mellitus, Type 2
Fukuoka, Japan
View Trial DetailsNCT03133156
Behavior, Body Weight
Boston, Massachusetts, United States
View Trial DetailsNCT04262128
Behavior, Cardiovascular Diseases
Aurora, Colorado, United States
View Trial DetailsNCT05563090
Cardiovascular Diseases, Diabete Mellitus
Singapore
View Trial Details